Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937297 | 0.81 | MEN1 (0.54) | GRM2FFAR1 | |
| SCHEMBL30506519 | 0.81 | MEN1 (0.54) | GRM2FFAR1 | |
| SCHEMBL1831691 | 0.79 | FFAR1 (0.47) | GRM2FFAR1 | |
| SCHEMBL4945327 | 0.79 | FFAR1 (0.47) | GRM2FFAR1 | |
| SCHEMBL6354449 | 0.78 | FFAR1 (0.50) | GRM2FFAR1 | |
| SCHEMBL2943808 | 0.77 | HPGD (0.50) | — | |
| SCHEMBL1829701 | 0.77 | KDM4E (0.44) | GRM2FFAR1 | |
| SCHEMBL15687580 | 0.76 | HPGD (0.56) | FFAR1 | |
| SCHEMBL20576950 | 0.76 | MAPT (0.47) | GRM2FFAR1 | |
| SCHEMBL1831012 | 0.76 | FFAR1 (0.44) | GRM2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | MERCK & CO., INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | GRM2 1/4885FFAR1 138/4885 |
| US-20050288346-A1 | Acetophenone potentiators of metabotropic glutamate receptors | GRM2, GRM1, GRIK2 | GRM2 1/4885FFAR1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.